Learn More

"Kainotomia," the innovative culture at Alnylam Pharmaceuticals
John Maraganore

Latest News

Alnylam Provides Key Goals and Guidance for Next 12 to 18 Months

Alnylam Pharmaceuticals Reports Third Quarter 2009 Financial Results

Management

Alnylam has assembled a team of passionate leaders from the biopharmaceutical industry bringing together their collective experiences of drug discovery, drug development, and commercialization.

John Maraganore, Ph.D., Chief Executive Officer: John Maraganore joined Alnylam in December 2002, bringing over 20 years of experience in Research and Development, and business roles with biotechnology companies. Prior to Alnylam he served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company's product franchises in Oncology, Cardiovascular, Inflammation, and Metabolic Diseases. He was previously Vice President, Strategic Planning and M&A and prior to that he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. (now Biogen Idec, Inc.). At Biogen, Dr. Maraganore invented and led the discovery and development of Angiomax^™ (bivalirudin for injection, formerly Hirulog^™) currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and The Upjohn Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. Dr. Maraganore is Chairman of Regulus Therapeutics, LLC, and a Director for Archemix, Inc., and Macrogenics, Inc. He is also a member of the Research Advisory Board of the Beth Israel Deaconess Hospital and a member of the Biotechnology Industry Organization Board.
Barry Greene, President and Chief Operating Officer: Barry Greene joined Alnylam in September 2003, and brings over 20 years of experience in healthcare, pharmaceutical, and biotechnology industries. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company's global strategy and execution for its oncology business including strategic business direction and execution, culminating in the successful approval and launch of VELCADE^™ (bortezomib) in mid 2003. Prior to joining Millennium in February 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene's past experiences include Vice President of Marketing and Customer Services for AstraZeneca formerly AstraMerck; Vice President Strategic Integration with responsibility for the AstraZeneca North American post merger integration; and Partner, Andersen Consulting responsible for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene received his B.S. in Industrial Engineering from University of Pittsburgh and serves as Senior Scholar at Duke University, Fuqua School of Business. Barry also serves on the Board of Acorda Therapeutics, Inc. and Regulus Therapeutics, LLC.
Akshay Vaishnaw, M.D., Ph.D., Senior Vice President, Clinical Research: Dr. Vaishnaw comes to Alnylam from Biogen, Inc. (now Biogen Idec Inc.), where he was most recently Senior Director, Translational Medicine. In his seven years at Biogen he was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (Amevive^™) for psoriasis. Dr. Vaishnaw received his M.D. from the University of Wales College of Medicine, U.K., with Distinctions in Pathology and Medicine, and his Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Member of the Royal College of Physicians, U.K., and received an Executive M.B.A. from Harvard Business School. In addition, Dr. Vaishnaw has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease.
Patricia Allen, Vice President Finance and Treasurer: Ms. Allen joined Alnylam in May 2004. Prior to Alnylam, she was at Alkermes, Inc. for 12 years, most recently as the Director of Finance, where she participated in multiple fundraising activities that exceeded $700 million. Ms. Allen also played key roles in significant merger and acquisition transactions. Prior to Alkermes, Ms. Allen was an Audit Manager at Deloitte & Touche LLP, an international public accounting firm. Ms. Allen is also a mentor with the Healthcare Business Women's Association (HBA). Ms. Allen is a certified public accountant.
Philip Chase, Vice President, Legal: Mr. Chase comes to Alnylam with over 10 years of legal experience, with a focus in the biotechnology industry. Prior to joining Alnylam, Mr. Chase served as Vice President and General Counsel at RenaMed Biologics. Before that, Mr. Chase served as Vice President and General Counsel of EPIX Pharmaceuticals, Inc. and played an integral role in the merger of EPIX and Predix Pharmaceuticals Holdings, Inc. Mr. Chase also served as Chief Corporate Counsel at Transkaryotic Therapies, Inc. Prior to moving into the biotechnology industry, Mr. Chase worked at the law firms of Skadden, Arps, Slate, Meagher & Flom LLP, and Shearman & Sterling LLP. He received his J.D. degree from Columbia University School of Law and his B.A. from Colby College.
Antonin (Tony) de Fougerolles, Ph.D., Vice President, Research, Immunology, Metabolic, and Viral Disease: Dr. de Fougerolles joined Alnylam in 2003 as Director of Research, and has played a key role in the development of several research programs including those with Alnylam partners Novartis and Roche, and in Alnylam Biodefense^™ programs. Prior to joining Alnylam, he served as a Principal Scientist at Biogen, Inc. (now Biogen Idec Inc.), where he worked since 1998. At Biogen, he worked on several immunology/inflammation-based programs and led research teams working to develop antibody-based therapeutics. Dr. de Fougerolles earned his Ph.D. in Immunology from Harvard University, and was a Research Fellow at the Laboratory of Molecular Biology in Cambridge, England.
David Konys, Vice President, Manufacturing Operations: Mr. Konys joined Alnylam in April 2003. He was formerly Vice President of Corporate Development at Ingenium Pharmaceuticals AG, and prior to that, had over 15 years of experience at Biogen, Inc. (now Biogen Idec Inc.), where he was the 1995 recipient of the Chairman's Award. During his career, Mr. Konys has been responsible for a wide array of activities related to the building and expansion of growing biotech companies, including establishing a wholly owned subsidiary, Biogen Canada, Inc., for which he was President & Managing Director, licensing intellectual property, directing the expansion of operations groups, and marketing.
Susanna High, Vice President, Business Planning and Program Management: Ms. High joined Alnylam in February 2006 as Senior Director, Business Planning and Program Management. Ms. High joined Alnylam from Millennium Pharmaceuticals, Inc., where she most recently was Director of Corporate Strategy and prior to that Director of Business Operations. From 1996 to 2001 Ms. High held a leadership role as management consultant with Accenture in their Strategy Pharmaceutical Practice. Ms. High has more than 15 years of operations, strategic and financial management experience, locally and internationally. She holds a degree in Economics and Business from Universita' Bocconi, Milan, Italy and a Masters in Business Administration from MIT.
Victor Kotelianski, M.D., Ph.D., D.Sc., Senior Vice President, Distinguished Alnylam Fellow: Dr. Kotelianski joined Alnylam in April 2003 as Vice President, Research and was promoted to Senior Vice President, Distinguished Alnylam Fellow in August 2008. Dr. Kotelianski was formerly Distinguished Investigator, Director of Biological Research at Biogen, Inc. (now Biogen Idec Inc.), where he worked since 1994. At Biogen, he played a leadership role in the development of the pre-clinical pipeline. In his prior experience, he served as Director of Research, Institut National de la Sante et de la Reserche Medicale (INSERM) in Paris, France. Dr. Kotelianski received his Doctor of Science degree from the National Cardiology Research Center, Academy of Medical Science in Moscow, and then went on to serve as the institute's Professor of Cell Biology there. He was senior scientist at the Institute of Protein Research, National Academy of Science in Poustchino (Moscow Region). Dr. Kotelianski received his Ph.D. in molecular biology from National Academy of Sciences in Moscow and his M.D. from Uzhgorod University Medical School; he is also an author on over 150 publications.
Muthiah (Mano) Manoharan, Ph.D., Senior Vice President, Drug Discovery: Dr. Manoharan was the former Executive Director of Medicinal Chemistry at Isis Pharmaceuticals, Inc., a leading biotechnology company focused on nucleic acid-based therapeutics where he had a 12-year tenure. With a distinguished career as a world-leading nucleic acid and bioconjugate chemist, Dr. Manoharan is an author on over 130 publications and over 200 abstracts, as well as the inventor on over 115 issued U.S. patents. Prior to Isis Pharmaceuticals, he earned his Ph.D. in chemistry at the University of North Carolina-Chapel Hill and conducted post-doctoral work at Yale University and the University of Maryland.
Saraswathy (Sara) Nochur, Ph.D., Vice President, Regulatory Affairs: Dr. Nochur has over 19 years of experience in the areas of product development and regulatory affairs. Most recently, she held the position of Vice President, Regulatory Affairs at The Medicines Company. Prior to her four years there, she served as Director, Product Development and Regulatory Affairs for CereMedix, Inc. Dr. Nochur also held senior positions at BioTrack, Inc. including Vice President, Product Development and Regulatory Affairs, and Chief Operating Officer. Prior to that she was employed by DynaGen, Inc. where she held positions of increasing responsibility, culminating in the role of Director, New Product Development. Dr. Nochur received her B.S. and M.S. degrees in Microbiology from the University of Bombay in India, and her Ph.D. in Biochemical Engineering at the MIT.
Stuart Pollard, Ph.D., Vice President, Scientific and Business Strategy: Dr. Pollard brings broad scientific and business expertise to Alnylam with almost 20 years of biotech experience. Prior to joining Alnylam, he was employed by Maxygen, Inc. where for eight years where he held positions of increasing responsibility across both scientific and business development initiatives, culminating in his most recent role as Chief Scientific Officer. Before Maxygen, Dr. Pollard worked at Biogen, Inc. (now Biogen Idec Inc.) for 10 years, during which time he held positions in both the R&D and business development organizations. Dr. Pollard earned his Ph.D. in Molecular Virology from the University of Reading in the U.K., and completed his post-doctoral work in the Department of Molecular Biology and Biochemistry at Harvard University.
Eric Raichle, Vice President, Human Resources: Mr. Raichle joins Alnylam with over 20 years of global human resources experience with expertise in employee relations, talent management, communication and organizational development. He has contributed to the success of several public and private companies including Bain & Company, Digitas LLC, and most recently served as the Director of Human Resources at Alkermes, Inc. He holds a B.A. in Industrial and Organizational Psychology from Suffolk University.
Dinah Sah, Ph.D., Vice President, Research, CNS, and Oncology: Dr. Sah joined Alnylam in April of 2005 as Senior Director, Research, after having served as Associate Director, Research, at Biogen Idec, Inc., where she led neurobiology research since 1999. At Alnylam, she established and helped build the CNS and Oncology efforts, including ALN-VSP, and leads the Huntington's program in collaboration with Medtronic, as well as the JCV Program in collaboration with Biogen Idec. While at Biogen Idec, Dr. Sah led research efforts in neuroscience and strategic planning for the neurobiology focus area, and was project leader of several research programs, including pain and spinal cord injury. From 1993 to 1999, Dr. Sah was a Scientist and then Associate Director of Neurobiology at Signal Pharmaceuticals in San Diego where she was project leader for neuroscience collaborations with Roche and Nippon Kayaku. She completed her post-doctoral training at Harvard Medical School and received her Ph.D. in Neurobiology from Harvard University.
Donna T. Ward, Ph.D., Vice President, Intellectual Property: Dr. Ward comes to Alnylam with nearly 10 years of industry experience, most recently as a patent attorney with the Elmore Patent Law Group where she represented companies in both the biotechnology and the pharmaceutical industries with a focus on strategic counseling and pharmaceutical lifecycle management. Previously, Dr. Ward spent seven years at Isis Pharmaceuticals, Inc. managing a significant portion of their chemistry and biology portfolios. Dr. Ward earned her J.D. from the Thomas Jefferson School of Law in San Diego and her Ph.D. in Biochemistry from the University of Kentucky, College of Medicine. She also received postdoctoral training at Vanderbilt University studying DNA adducts.